Cargando…

Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade

BACKGROUND: Paraneoplastic acral vascular syndrome (PAVS) is a rare phenomenon which is observed in patients with adenocarcinomas and other malignancies. Various potential pathogenic mechanisms such as tumour invasion of sympathetic nerves, hyperviscosity, hypercoagulability, vasoactive tumour-secre...

Descripción completa

Detalles Bibliográficos
Autores principales: Gambichler, Thilo, Strutzmann, Stefanie, Tannapfel, Andrea, Susok, Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429577/
https://www.ncbi.nlm.nih.gov/pubmed/28499411
http://dx.doi.org/10.1186/s12885-017-3313-6
_version_ 1783236051901349888
author Gambichler, Thilo
Strutzmann, Stefanie
Tannapfel, Andrea
Susok, Laura
author_facet Gambichler, Thilo
Strutzmann, Stefanie
Tannapfel, Andrea
Susok, Laura
author_sort Gambichler, Thilo
collection PubMed
description BACKGROUND: Paraneoplastic acral vascular syndrome (PAVS) is a rare phenomenon which is observed in patients with adenocarcinomas and other malignancies. Various potential pathogenic mechanisms such as tumour invasion of sympathetic nerves, hyperviscosity, hypercoagulability, vasoactive tumour-secreted substances, and immunological mechanisms have been suggested. CASE PRESENTATION: We report a 60-year-old Caucasian male attended our hospital with a bulky lymph node mass in the right axilla. Extirpation of a lymph node conglomerate revealed 5 melanoma lymph node metastases. Computed tomography showed a liver metastasis (diameter: 3.8 cm), several retroperitoneal metastases, bilateral metastases in the lung hilus, and prepectoral subcutaneous metastases (Stage IV; pTx, N3, M1c). Lactate dehydrogenase and S100B were slightly elevated. Combination therapy of nivolumab (1 mg/kg BW) and ipilimumab (3 mg/kg BW) was started. Three weeks after the first combination therapy he developed progressive erythema, paraesthesia and pain on the fingertips of both hands. Both cold and warmth was not well tolerated by the patient. Complete work-up excluded associated conditions or factors such as haematological disorders, rheumatologic disorders, hypertension, diabetes or smoking. Treatment was initiated with prostacyclin 20 μg twice daily and oral prednisolone 50 mg in tapering dosage. However, prostacyclin was stopped after the first applications because the pain increased during infusion. The second course of nivolumab and ipilimumab was administered. About 2 weeks later, the patient presented with increased pain and small subungual necrosis. We treated the patient with oral analgetics and intravenous prednisolone 500 mg in tapering dosage. On digital substraction angiography occlusion of all arteries of the fingers was demonstrated. Further rheologic and anti-melanoma treatments were refused by the patient. About 2 months after the second course of nivolumab and ipilimumab combination therapy several fingers showed severe gangrene which finally led to amputations of end phalanges of several fingers. Histopathology did not reveal evidence for vasculitis or other primary vascular pathologies. During the following 2 months the patient experienced dramatic progress of his metastatic disease and finally died at multi-organ failure. CONCLUSION: Presence of rapidly progressive digital ischemia in an elderly patient with cancer should always raise clinical suspicion of a paraneoplastic phenomenon when other possible causes have been excluded. In patients treated with immune checkpoint inhibitors such as CTLA-4 and PD-L1 blockers PVAS-like events have not been reported so far. However, it is debatable whether immune checkpoint blockade may play a pathogenetic role in the development of PAVS in patients with malignancies.
format Online
Article
Text
id pubmed-5429577
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-54295772017-05-15 Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade Gambichler, Thilo Strutzmann, Stefanie Tannapfel, Andrea Susok, Laura BMC Cancer Case Report BACKGROUND: Paraneoplastic acral vascular syndrome (PAVS) is a rare phenomenon which is observed in patients with adenocarcinomas and other malignancies. Various potential pathogenic mechanisms such as tumour invasion of sympathetic nerves, hyperviscosity, hypercoagulability, vasoactive tumour-secreted substances, and immunological mechanisms have been suggested. CASE PRESENTATION: We report a 60-year-old Caucasian male attended our hospital with a bulky lymph node mass in the right axilla. Extirpation of a lymph node conglomerate revealed 5 melanoma lymph node metastases. Computed tomography showed a liver metastasis (diameter: 3.8 cm), several retroperitoneal metastases, bilateral metastases in the lung hilus, and prepectoral subcutaneous metastases (Stage IV; pTx, N3, M1c). Lactate dehydrogenase and S100B were slightly elevated. Combination therapy of nivolumab (1 mg/kg BW) and ipilimumab (3 mg/kg BW) was started. Three weeks after the first combination therapy he developed progressive erythema, paraesthesia and pain on the fingertips of both hands. Both cold and warmth was not well tolerated by the patient. Complete work-up excluded associated conditions or factors such as haematological disorders, rheumatologic disorders, hypertension, diabetes or smoking. Treatment was initiated with prostacyclin 20 μg twice daily and oral prednisolone 50 mg in tapering dosage. However, prostacyclin was stopped after the first applications because the pain increased during infusion. The second course of nivolumab and ipilimumab was administered. About 2 weeks later, the patient presented with increased pain and small subungual necrosis. We treated the patient with oral analgetics and intravenous prednisolone 500 mg in tapering dosage. On digital substraction angiography occlusion of all arteries of the fingers was demonstrated. Further rheologic and anti-melanoma treatments were refused by the patient. About 2 months after the second course of nivolumab and ipilimumab combination therapy several fingers showed severe gangrene which finally led to amputations of end phalanges of several fingers. Histopathology did not reveal evidence for vasculitis or other primary vascular pathologies. During the following 2 months the patient experienced dramatic progress of his metastatic disease and finally died at multi-organ failure. CONCLUSION: Presence of rapidly progressive digital ischemia in an elderly patient with cancer should always raise clinical suspicion of a paraneoplastic phenomenon when other possible causes have been excluded. In patients treated with immune checkpoint inhibitors such as CTLA-4 and PD-L1 blockers PVAS-like events have not been reported so far. However, it is debatable whether immune checkpoint blockade may play a pathogenetic role in the development of PAVS in patients with malignancies. BioMed Central 2017-05-12 /pmc/articles/PMC5429577/ /pubmed/28499411 http://dx.doi.org/10.1186/s12885-017-3313-6 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Case Report
Gambichler, Thilo
Strutzmann, Stefanie
Tannapfel, Andrea
Susok, Laura
Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
title Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
title_full Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
title_fullStr Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
title_full_unstemmed Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
title_short Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
title_sort paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5429577/
https://www.ncbi.nlm.nih.gov/pubmed/28499411
http://dx.doi.org/10.1186/s12885-017-3313-6
work_keys_str_mv AT gambichlerthilo paraneoplasticacralvascularsyndromeinapatientwithmetastaticmelanomaunderimmunecheckpointblockade
AT strutzmannstefanie paraneoplasticacralvascularsyndromeinapatientwithmetastaticmelanomaunderimmunecheckpointblockade
AT tannapfelandrea paraneoplasticacralvascularsyndromeinapatientwithmetastaticmelanomaunderimmunecheckpointblockade
AT susoklaura paraneoplasticacralvascularsyndromeinapatientwithmetastaticmelanomaunderimmunecheckpointblockade